Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEXL -- Ignore unavailable to you. Want to Upgrade?

To: Anthony G. Breuer who wrote (1360)	4/17/1998 6:10:00 PM
From: Augmeister	Read Replies (1) \| Respond to of 1704

relax...the next big news will be Isolex...a yes or a delay...a yes and we will be off to the races until the wound healing agent or the hypericin skin test are finished with good results and FDA approval...late 1999 or 2000...a delay...and we wait some more. this is not a fly by night operation...vmrx is operating like a virtual company...owning the majority of the companies that will fuel its growth..yes, if any of the affiliates take off, we all win! my bet is that we will get Isolex done. i have read some of dr. rook's studies on hypericin on the derma studies at UPenn and IMHO, this looks like a commercially viable ($$$) product with a big market and large shelf life. the other deals will all be done over the next 4-5 years and that will be the gravy. isolex will get us to that 5-7 range by next summer and the vimrxyn for derma and the potential wound healing compound will make the patient ones on this board, glad to be americans.